The ‘Guideline on risk management systems for medicinal products for human use’ from the EMEA, adopted in November 2005.
PSUR AND RISK MANAGEMENT
The
‘Guideline on risk management systems for medicinal products for human use’
from the EMEA, adopted in November 2005, clearly states that risk management
plan (RMP) and its updates should be submitted at the same time as the PSURs
unless other requirements have been laid down as a condition of the marketing
authorisation. This RMP is now requested from health authorities for all new
appli-cations. In general, safety issues should be identified at early stages
in the development of a compound, and these issues be approached in a RMP. This
RMP can then propose different actions to counteract or better understand these
issues: education (physicians, patients, sales representatives etc.), step-wise
market approach, use of utilisation and/or safety databases, specific studies
targeting defined issues and so on. The RMP will serve as a guiding document,
and assess-ment of the plan will be reported in the PSUR. The PSUR is thus now
the document in which all the available information on safety of a given
product is gathered from all sources, such as clinical trials, observational
studies, spontaneous reports and also pre-clinical experiments, and put into
perspective. The consistency of a potential signal/issue across all the sources
is of very high value. The PSUR will help in that analysis because it is a
unique document assem-bling all these information from multiple sources.
Related Topics
TH 2019 - 2026 pharmacy180.com; Developed by Therithal info.